2.48 USD
↘ 0.13 (4.98%)AT CLOSE (03:59 PM EDT)
Rocket Pharmaceuticals, Inc. Common Stock
RCKTNASDAQ • USD
2.54
↗ 0.06 (2.38%)
POST MARKET (AS OF 07:53 PM EDT)
Post Market
AS OF 07:53 PM EDT
2.54
↗ 0.06 (2.38%)
Market: OPEN
Rocket Pharmaceuticals, Inc. Common Stock (RCKT) trades at $2.54 per share. Both sides of the analysis point lower: technicals flash "Strong Sell" and fundamentals confirm with a "Sell" reading. Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. The stock looks compelling on valuation, with multiples below sector averages across P/E, P/B, and EV/EBITDA.
Technical & fundamental data as of Oct 6, 2026.
Open?$2.61
High?$2.62
Low?$2.46
Prev. Close?$2.61
Volume?1.8M
Avg. Volume?1.8M
VWAP?$2.51
Rel. Volume?1.00x
Bid / Ask
Bid?$2.11 × 100
Ask?$2.84 × 100
Spread?$0.73
Midpoint?$2.47
Valuation & Ratios
Market Cap?286.5M
Shares Out?109.8M
Float?84.6M
Float %?77.5%
P/E Ratio?N/A
P/B Ratio?0.78
EPS?-$0.16
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
Themes
Employees
202
Market Cap
286.5M
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2015-02-18
Address
350 FIFTH AVENUE
NEW YORK, NY 10118
Phone: 646-440-9100
NEW YORK, NY 10118
Phone: 646-440-9100
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-2/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?0
Momentum?65
Short Sent.?19
Piotroski F-Score?0/9Weak
Altman Z-Score?-2.11Distress
Confidence?54%Low
Short InterestVery High
Short % of Float?17.55%High
Short Interest?14.8M
Days to Cover?11.1
Free Float84.6M
Avg Daily Volume1.3M
Settlement Date2026-09-15
Financial Health
Current Ratio?9.24Strong
Quick Ratio?9.24Strong
Cash Ratio?7.17Strong
Debt/Equity?0.06Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score100/100
P/E?N/A▾
P/B?0.78CHEAP▾
Peers100
S&P97
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-0.5CHEAP▾
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-4.7%WEAK▾
S&P11
ROA?-4.1%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-170394000
Enterprise Value?$83.3M
Fundamentals ratios updated end of day